Orchestra BioMed
OBIO
39 hedge funds and large institutions have $75.5M invested in Orchestra BioMed in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
77% more funds holding
Funds holding: 22 → 39 (+17)
1.08% less ownership
Funds ownership: 31.24% → 30.16% (-1.1%)
61% less capital invested
Capital invested by funds: $193M → $75.5M (-$118M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$7.62M |
| 2 |
BlackRock
New York
|
+$2.29M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.34M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$3.42M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.18M |
| 3 |
HF
HRT Financial
New York
|
-$568K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$502K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$196K |
OBIO Hedge Fund Activity: Q2 2023 in Review
39 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2023, worth a combined $75.5M — down 61% from $193M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new OBIO positions and 3 closed out — a net gain of 17 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was RTW Investments, adding an estimated $7.62M. The largest seller was Perceptive Advisors, cutting an estimated $3.42M.
- 39 institutional investors held Orchestra BioMed (OBIO) as of Q2 2023, up from 22 in Q1 2023.
- Funds reported $75.5M of Orchestra BioMed stock for Q2 2023, down 61% quarter-over-quarter.
- 20 funds opened new Orchestra BioMed positions in Q2 2023 and 3 closed out, a net change of +17 holders.
- The largest Orchestra BioMed buyer in Q2 2023 was RTW Investments, an estimated $7.62M added.
- The largest Orchestra BioMed seller in Q2 2023 was Perceptive Advisors, an estimated $3.42M sold.
Based on aggregated 13F filings for Q2 2023.